APOC3 Loss Of Function Mutations, Remnant Cholesterol, Low Density Lipoprotein Cholesterol, And Cardiovascular Risk Mediation And Meta Analyses Of 137 895 Individuals Anders B. Wulff, Børge G. Nordestgaard, Anne Tybjærg Hansen

This research examined how genetic mutations affecting the APOC3 protein impact heart disease risk and cholesterol levels. APOC3 is a protein that helps regulate how our bodies process fats in the blood. When people have "loss-of-function" mutations in the gene that makes this protein, their bodies produce less functional APOC3, which changes how they metabolize fats.

The study found that people with these APOC3 mutations had dramatically better cardiovascular outcomes. Compared to people without the mutations, those with the genetic variants had approximately 40% lower risk of ischemic vascular disease (heart attacks and strokes caused by blocked blood vessels). These individuals also had 39-44% lower triglyceride levels and 46% lower levels of the APOC3 protein itself.

The researchers believe the heart-protective effect comes from lower levels of "remnant cholesterol" - a type of cholesterol carried in fat-rich particles in the blood. Unlike triglycerides, cholesterol is what actually builds up in artery walls to cause blockages. Remnant cholesterol can be easily calculated from standard cholesterol tests by subtracting LDL and HDL cholesterol from total cholesterol. The study also referenced clinical trials using APOC3-blocking medications that showed similar dramatic reductions in triglycerides.

This research is significant for metabolic health because it identifies remnant cholesterol as an important target for preventing heart disease, beyond just focusing on LDL ("bad") cholesterol. In clinical practice, this suggests that measuring and managing remnant cholesterol levels could be valuable for assessing cardiovascular risk, and that medications targeting the APOC3 pathway may offer new treatment options for patients with elevated triglycerides and remnant cholesterol.